Click Therapeutics initiates OLE study for digital therapeutic in schizophrenia
Click Therapeutics has initiated an open label extension study to evaluate the maintained efficacy and safety of a second consecutive course of its digital therapeutic, the Click Therapeutics Study App, as an adjunct treatment to standard of care in schizophrenia.
Phase III
Neurology / Schizophrenia
Status
Initiated
Sponsor
Click Therapeutics
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The initiation of this extension study may influence portfolio prioritization for companies developing digital therapeutics, highlighting the potential for adjunctive treatments in schizophrenia management.
Why it matters
The initiation of the open label extension study for Click Therapeutics' digital therapeutic in schizophrenia is a pivotal moment for stakeholders across the pharmaceutical and digital health sectors.
Recommended action
Humanexa recommends Monitor: Monitoring the results of the open label extension study is essential as it will provide critical data on the efficacy and safety of the digital therapeutic in a real-world setting. This information will be pivotal for assessing the potential for regulatory approval and market acceptance, as well as for understanding its competitive positioning against traditional therapies and other digital solut
Analysis
Monitor results from the OLE study and any subsequent regulatory filings or partnerships that may arise from its outcomes.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.